Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

NCT01639339 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

448

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

BIOLOGICAL: Placebo plus standard therapy
BIOLOGICAL: Belimumab 10 mg/kg plus standard therapy
DRUG: Standard therapy

Sponsor

Human Genome Sciences Inc., a GSK Company

Collaborators

[object Object]